Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8361729 | Seminars in Cancer Biology | 2018 | 39 Pages |
Abstract
Each year, almost 4.1 million people are diagnosed with gastrointestinal (GI) cancers. Due to late detection of this disease, the mortality is high, causing approximately 3 million cancer-related deaths annually, worldwide. Although the incidence and survival differs according to organ site, earlier detection and improved prognostication have the potential to reduce overall mortality burden from these cancers. Epigenetic changes, including aberrant promoter DNA methylation, are common events in both cancer initiation and progression. Furthermore, such changes may be identified non-invasively with the use of PCR based methods, in bodily fluids of cancer patients. These features make aberrant DNA methylation a promising substrate for the development of disease biomarkers for early detection, prognosis and for predicting response to therapy. In this article, we will provide an update and current clinical perspectives for DNA methylation alterations in patients with colorectal, gastric, pancreatic, liver and esophageal cancers, and discuss their potential role as cancer biomarkers.
Keywords
FDAqMSPFOBTMSPESCCEACPSCCCAROCAUCHCCmethylation specific PCRPFsPancreatic ductal adenocarcinomaEsophageal adenocarcinomaPDAC یا pancreatic ductal adenocarcinomafecal immunochemical testfecal occult blood testUS Food and Drug AdministrationProgression free survivaloverall survivalDetectionGastrointestinalGastrointestinal cancersDNA methylationFITReceiver operating characteristics curvearea under the ROC curveBiomarkersprognosisEsophageal squamous cell carcinomaHepatocellular carcinomaPrimary sclerosing cholangitisCholangiocarcinoma
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Hege Marie Vedeld, Ajay Goel, Guro E. Lind,